The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares a comparative analysis of the safety and efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T-cell therapy, and mosunetuzumab, a CD20xCD3 bispecific antibody, in the treatment of third line (3L) or later relapsed/refractory (R/R) follicular lymphoma (FL). Utilizing data from two clinical trials (TRANSCEND FL; NCT04245839, GO29781; NCT02500407), a matching-adjusted indirect comparison (MAIC) highlights that liso-cel demonstrates superior efficacy and a lower incidence of high-grade adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: ADC Therapeutics, Bristol Myers Squibb/Celgene, Caribou Biosciences, AbbVie, DeNovo, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Regeneron, AstraZeneca, Gilead Sciences/Kite Pharma
Research Funding: Bristol Myers Squibb/Celgene, Caribou Biosciences, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Gilead Sciences/Kite Pharma
